Red Light Therapy for Pneumonia: What the Evidence Shows About Photobiomodulation and Lung Inflammation

TL;DR

• Pneumonia is a serious lung infection (bacterial, viral, or fungal) that requires medical diagnosis and appropriate treatment (antibiotics for bacterial pneumonia, antivirals where indicated). Red light therapy is not a treatment for pneumonia and must never replace prescribed medications.
• Two small clinical trials in COVID-19 pneumonia patients have shown meaningful signals: a 10-patient randomised trial found 0% ICU admission in the PBMT group vs 40% mortality in the control group; a 52-patient double-blind RCT found IL-6 and TNF-α reduced by ~82% after 72 hours of PBM. Both studies are preliminary and involved COVID-19, not general pneumonia.
• The proposed mechanisms (reduced pro-inflammatory cytokines, improved mitochondrial ATP production, and enhanced microcirculation) are biologically plausible and consistent with PBM's established effects in other inflammatory conditions. They have not been confirmed in large-scale bacterial pneumonia trials.
• The most reasonable application of consumer red light therapy for pneumonia is as adjunctive support during recovery, targeting chest inflammation, fatigue, and general immune support, not as a substitute for medical treatment at any stage.
• If you have pneumonia symptoms (fever, productive cough, shortness of breath, chest pain), see a GP immediately. Do not use red light therapy in place of or as a reason to delay seeking medical care.

Pneumonia kills more than 2.5 million people globally each year and remains a leading cause of hospitalisation in Australia. It is caused by infection: bacterial (most commonly Streptococcus pneumoniae), viral (including influenza and SARS-CoV-2), or fungal, triggering an inflammatory response in the alveoli that impairs oxygen exchange. Treatment depends on the pathogen: bacterial pneumonia requires antibiotics; viral pneumonia is managed supportively or with antivirals where available.

Red light therapy (photobiomodulation) has attracted interest as a potential adjunctive tool in respiratory inflammation, particularly after COVID-19 generated early clinical trials that would not have been funded under ordinary timelines. This guide covers what those trials showed, the underlying mechanisms, the honest evidence position, and how consumer devices might be used responsibly during recovery.

What Is Pneumonia and Why Does Inflammation Matter?

Pneumonia triggers acute alveolar inflammation: the immune response releases cytokines including IL-6, IL-8, and TNF-α, causing the fluid accumulation that impairs gas exchange. In severe cases, this inflammatory response can become dysregulated. The cytokine storm associated with severe COVID-19 drives systemic organ stress beyond the lungs. This inflammatory cascade is where photobiomodulation has the most plausible mechanistic relevance: not at the pathogen, but at the immune-mediated lung damage.

How Photobiomodulation Interacts With Lung Inflammation

Red and near-infrared wavelengths (typically 620–670nm and 808–850nm) penetrate tissue and are absorbed by cytochrome c oxidase in the mitochondrial electron transport chain, increasing ATP production and generating downstream signalling that modulates the inflammatory response. The specific mechanisms relevant to pneumonia recovery include:

• Cytokine reduction: PBM downregulates pro-inflammatory cytokines including IL-6, IL-8, and TNF-α, the same markers elevated in severe pneumonia and COVID-19 cytokine storm. The double-blind RCT discussed below measured this directly in hospitalised patients.
• Mitochondrial support: Infection and inflammation reduce cellular energy production. PBM-stimulated ATP synthesis supports the metabolic demands of immune cell function and tissue repair.
• Microcirculation: Near-infrared light promotes nitric oxide release from haemoglobin, improving local vasodilation and oxygen delivery to tissues under inflammatory stress.
• Tissue repair: Fibroblast activation and collagen synthesis support recovery from lung tissue damage after the acute infection resolves.

These mechanisms are well-established in the PBM literature for other conditions; their specific application to lung inflammation is where the evidence base is still early.

What the Clinical Evidence Shows

The Dovepress RCT: Cytokine Reduction in COVID-19 Pneumonia

The most rigorous study to date is a randomised, double-blind, placebo-controlled pilot trial published in the Journal of Inflammation Research (2021). Fifty-two hospitalised adults with mild-to-moderate COVID-19 pneumonia were randomised to PBM (n=24) or sham placebo (n=28). The PBM group received red light at 620–635nm across five devices on the chest, back, and neck at 45.40 J/cm² per session, twice daily for three days, alongside standard care.

Results at 72 hours: IL-6 fell by approximately 82.5% in the PBM group with no significant change in the placebo group; TNF-α fell by 82.4%; IL-8 fell by 54.4%. No adverse effects were reported. The authors cautioned that the 3-day duration was insufficient to assess clinical outcomes and called for larger trials.

The Open-Label Pilot: Clinical Outcomes

An earlier open-label pilot (2021) treated 10 hospitalised COVID-19 patients with adjunctive PBM (808nm + 905nm, ~7.18 J/cm², once daily for 4 days over the posterior chest) or standard care. Outcomes diverged sharply: zero PBMT patients required ICU admission or ventilation; in the control group, 3 of 5 were ventilated and 2 of 5 died. Pulmonary severity scores improved significantly in the PBMT group and worsened in controls. The authors noted major limitations: 5 patients per arm, open-label design, and a manufacturer-affiliated author. The findings were framed as hypothesis-generating.

Animal and Preclinical Evidence

Preclinical studies in sepsis-induced acute lung injury models found reduced alveolar damage, lower cytokine expression, and improved tissue architecture in PBM-treated animals. These results support the plausibility of the clinical findings but cannot directly predict human outcomes in infection-driven pneumonia.

The Honest Evidence Position

The clinical evidence for PBM in pneumonia is early. Both human trials involved COVID-19 specifically and not bacterial pneumonia, and are small, preliminary studies with significant methodological limitations. No large-scale RCT exists for PBM in COVID-19 or general pneumonia. Consumer devices also differ from the clinical devices used in these trials in wavelengths, power density, and delivery. These findings are promising but do not establish PBM as a proven treatment for pneumonia of any cause.

Safety Considerations

Pneumonia can deteriorate rapidly. Bacterial pneumonia untreated with appropriate antibiotics can progress to sepsis and respiratory failure within hours. This is not a condition where delayed or declined medical care is appropriate.

• Seek immediate medical assessment if you have fever, productive cough, shortness of breath, chest pain, or confusion: these are pneumonia warning signs requiring GP or emergency evaluation.
• Do not delay antibiotics or antivirals to try red light therapy first. Prescribed antimicrobial treatment is the primary intervention for bacterial pneumonia. PBM is adjunctive, used alongside medical care and not instead of it.
• Appropriate timing: The clinical trials applied PBM to hospitalised patients already receiving standard care. In a community context, the most appropriate window is during the recovery phase after medical assessment and treatment have begun.
• Consult your GP before using red light therapy if you have active pneumonia, severe hypoxia, or underlying respiratory disease (COPD, asthma, pulmonary fibrosis).
• Emergency signs: Worsening breathlessness, cyanosis, high fever not responding to treatment, confusion, or chest pain require emergency medical attention regardless of any home therapy in use.

How to Use Red Light Therapy During Pneumonia Recovery

• Medical clearance first. Confirm with your GP that treatment is initiated and your condition is improving before adding any adjunctive approach.
• Target the posterior and anterior chest. Apply to the upper and mid-back and the front of the chest. The clinical trials used posterior chest application with the patient prone.
• Red + NIR combination wavelengths (660nm + 850nm) for anti-inflammatory and tissue recovery support. Sessions of 10–20 minutes, once or twice daily during active recovery.
• Rest and hydrate. Complete the full prescribed antibiotic course regardless of how quickly symptoms improve.
• Cease and seek medical review if symptoms worsen (returning fever, worsening breathlessness, new chest pain) at any point during recovery.

StreamShop Devices for Respiratory Recovery Support

LED Light Therapy Dome With 1064nm ($399.99)

StreamShop's LED light therapy dome with 1064nm delivers 660nm, 850nm, and 1064nm across 240 triple-chip LEDs at 87.4 mW/cm². The arch format provides hands-free chest coverage in a reclining position, which is practical during the fatigue associated with pneumonia recovery, without requiring the user to hold a device over the chest.

SS100 Red Light Panel With 1060nm ($749.99)

StreamShop's SS100 red light panel with 1060nm delivers 9 wavelengths (480nm, 590nm, 630nm, 660nm, 670nm, 810nm, 830nm, 850nm, and 1060nm) at 160 mW/cm² or greater through 72 dual-chip LEDs. ARTG listed with per-wavelength dimming and pulse frequency control (1–10,000Hz). The 1060nm wavelength provides the deepest tissue penetration of any StreamShop device, relevant for reaching posterior lung tissue when positioned behind the user.

Red Light Therapy Mat With Near-Infrared ($949.99)

StreamShop's red light therapy mat with near-infrared delivers 660nm and 850nm across 1,280 triple-chip LED beads over a full 180cm body surface. Lying on the mat allows passive posterior chest coverage, covering the back surface of both lungs simultaneously, with minimal physical effort, suited to pneumonia recovery fatigue.

Frequently Asked Questions

Can Red Light Therapy Treat Pneumonia?

No. Bacterial pneumonia requires antibiotics; viral pneumonia is managed with antivirals and supportive care. Red light therapy has no antimicrobial activity and is not a substitute for prescribed medical treatment. Two small preliminary trials in COVID-19 pneumonia found significant reductions in inflammatory cytokines and promising clinical outcome signals, but these are early findings in a specific viral context. PBM may be useful as an adjunctive support tool during recovery, alongside medical care and not instead of it.

What Did the COVID-19 Trials Actually Show?

A double-blind RCT (n=52) found three days of red light PBM at 620–635nm reduced IL-6 and TNF-α by approximately 82% in hospitalised COVID-19 patients vs no change in placebo, representing meaningful anti-inflammatory effects in the acute phase. A separate 10-patient open-label trial found daily near-infrared PBM over four days was associated with 0% ICU admission vs 40% mortality in untreated controls. Both trials have major limitations: very small samples, COVID-19 context only, and manufacturer-affiliated authorship in one.

Is Red Light Therapy Safe During Acute Pneumonia?

The clinical trials applied PBM to hospitalised patients as an add-on to standard care and reported no adverse effects. In a home setting, the primary risk is not the device itself but using it as a reason to delay medical assessment or treatment. Pneumonia can worsen rapidly. Consumer red light therapy should only be considered during recovery after medical evaluation and treatment have been initiated.

What Wavelengths Are Most Relevant for Lung Inflammation?

The clinical trials used 620–635nm (red) and 808–905nm (near-infrared). Red wavelengths are absorbed more superficially; near-infrared penetrates more deeply into posterior lung tissue. Both cytokine-reducing and tissue-repair mechanisms are supported across the 620–850nm range. The 1060nm wavelength in some StreamShop devices provides deeper penetration, though this has not been tested specifically in respiratory applications.

Can Red Light Therapy Help With Post-COVID Lung Symptoms?

Post-COVID pulmonary symptoms (persistent cough, breathlessness, reduced exercise tolerance) involve residual inflammation, microstructural lung damage, and autonomic dysfunction. PBM's anti-inflammatory and tissue-repair mechanisms are theoretically relevant. No clinical trials have specifically tested PBM for post-COVID pulmonary symptoms as a distinct endpoint. Persistent respiratory symptoms after COVID-19 should be assessed by a GP for post-COVID care referral.

How Is Photobiomodulation Different From Photodynamic Therapy?

Photodynamic therapy (PDT) uses a photosensitising agent activated by light to generate reactive oxygen species, used clinically for some cancers and skin conditions. Photobiomodulation works through mitochondrial light absorption and downstream anti-inflammatory signalling, with no photosensitising agent. The two mechanisms are entirely different and not interchangeable. PDT has no established role in pneumonia; PBM is the mechanism investigated in the lung inflammation trials above.